Status:
RECRUITING
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
Foundation for Research in Rheumatology (FOREUM)
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Accelerated atherosclerosis is an established complication of systemic autoimmune diseases, particularly SLE. Young female patients with SLE are more likely to develop myocardial infarction than match...
Eligibility Criteria
Inclusion
- Adult patient aged over 18 years old.
- SLE diagnosis according to the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus
- Having signed an informed consent (at the latest on the day of inclusion and before any examination required by research).
Exclusion
- Pregnancy or breast-feeding for woman.
- Person concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent
Key Trial Info
Start Date :
March 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04276701
Start Date
March 10 2021
End Date
March 1 2027
Last Update
November 13 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - service de médecine interne
Bordeaux, France
2
CHU de Brest - service de rhumatologie
Brest, France
3
CHRU de Lille - service de Médecine Interne
Lille, France
4
AP-HP - Hôpital Cochin - service de Médecine Interne
Paris, France